Abdullah Al-Asmi
Overview
Explore the profile of Abdullah Al-Asmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
2.
Siriratnam P, Huda S, van der Walt A, Sanfilippo P, Sharmin S, Foong Y, et al.
Neurology
. 2024 Nov;
103(12):e209940.
PMID: 39561307
Objectives: In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity...
3.
Al-Dhahri M, Helmy M, Rajeev N, Al Toubi A, Al-Abdali H, Al-Asmi A, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518455
: Multiple sclerosis (MS) is a chronic neurological disorder characterized by various clinical presentations and manifestations that include biopsychosocial impediments. This study has three interrelated goals relevant to biopsychosocial functioning:...
4.
Al-Shibli R, Al-Asmi A, Islam M, Al Sabahi F, Al-Aamri A, Butt M, et al.
Int J Environ Res Public Health
. 2024 Oct;
21(10).
PMID: 39457344
(1) Background and Aims: The seasonal factors influencing multiple sclerosis (MS) relapses remain elusive. This study aims to investigate the seasonal variation of MS relapses in Oman and compare it...
5.
Yeh W, van der Walt A, Skibina O, Kalincik T, Alroughani R, Kermode A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200328.
PMID: 39442037
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS...
6.
Al-Asmi A, Al-Jabri F, Al-Amrani S, Al Farsi Y, Al Sabahi F, Al-Futaisi A, et al.
Oman Med J
. 2024 Oct;
39(3):e628.
PMID: 39435390
Objectives: There is a dearth of research regarding the motivations and experiences of Omani nationals who travel abroad for medical treatment, especially for neurological diseases. The primary objective was to...
7.
Al-Asmi A, Al Sabahi F, Al-Adawi S, Al-Yaqoubi I, Jaju S, Chan M, et al.
Oman Med J
. 2024 Sep;
39(3):e629.
PMID: 39323425
Objectives: Several studies have explored the opinions of healthcare workers on the use of complementary and alternative medicine (CAM) in epilepsy treatment. We sought to survey the views of non-neurologist...
8.
Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong Y, Yeh W, et al.
J Neurol Neurosurg Psychiatry
. 2024 Sep;
PMID: 39231582
Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade,...
9.
Zeineddine M, Al-Roughani R, Farouk Ahmed S, Khoury S, El-Ayoubi N, Al-Mahdawi A, et al.
Mult Scler
. 2024 Jul;
30(8):1026-1035.
PMID: 39054846
Introduction: One strategy to mitigate progressive multifocal leukoencephalopathy (PML) risk is to switch to other highly effective disease-modifying therapies (DMTs). However, the optimal switch DMT following natalizumab (NTZ) discontinuation is...
10.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, et al.
PLOS Digit Health
. 2024 Jul;
3(7):e0000533.
PMID: 39052668
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the...